EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 365 participants.

Also called NCT02816736

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 365 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02816736
Other papers using this trial's data
  • Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial JAMA cardiology, 2022-01-01 DOI, PubMed 34730769, PMC8567189 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02816736. Randomized; triple masking; primary purpose treatment. Start 2017-03-02 (actual); primary completion 2020-09-15 (actual). Results posted on 2021-12-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)
Acronym
HFN-LIFE
Condition
Heart Failure
Intervention (Drug)
LCZ696
Intervention (Drug)
valsartan
Intervention (Drug)
LCZ696 placebo
Intervention (Drug)
valsartan placebo
Lead sponsor
Duke University (class: other)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct02816736
Content hash
53118fd7d80c6d507091c4e67aa858c77524a758b3d0c7ed5fae742861b8187a